Kinga Porter, DO
Hospitalist · Lakewood Ranch, FLNPI 1154646099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,000 and has fallen 51.6% since, to $484 in 2025. Among hospitalist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$581
- Amgen$515
- Currax Pharmaceuticals LLC$402
- AstraZeneca$386
- Novo Nordisk$334
- Lilly USA, LLC$320
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,10699%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $581 |
| Amgen | 21 | $515 |
| Currax Pharmaceuticals LLC | 34 | $402 |
| AstraZeneca | 7 | $386 |
| Novo Nordisk | 18 | $334 |
| Lilly USA, LLC | 19 | $320 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $282 |
| IBSA Pharma Inc. | 6 | $144 |
| Davol Inc. | 1 | $138 |
| Novartis | 1 | $121 |
| Axsome Therapeutics, Inc. | 4 | $111 |
| Smith+Nephew | 1 | $103 |
| Genentech USA, Inc. | 1 | $100 |
| Johnson & Johnson | 3 | $73 |
| Organon | 2 | $69 |
| Radius Health, Inc. | 3 | $62 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Romark Laboratories, LC | 4 | $41 |
| Abiomed | 1 | $36 |
| Astellas Pharma US Inc | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Pfizer | 1 | $22 |
| Mentor Worldwide LLC | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Optinose US, Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$342
- Phasix Mesh$138
- Repatha$127
- QULIPTA$124
- ENTRESTO$121
- VRAYLAR$116
- ACTICOAT 4" X 4"$103
- ALLEVYN HEEL 10.5CM X 13.5CM CTN 5$103
- Iodosorb Ointment 40g USA$103
- COLLAGENASE SANTYL$103
How this compares
$4,131 in reported general payments places this provider in the 95th percentile of 1,570 hospitalist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 17 | $19,421 |
| XareltoRivaroxaban | 15 | $18,302 |
| EliquisApixaban | 28 | $14,289 |
| Praluent PenAlirocumab | 12 | $12,801 |
| MounjaroTirzepatide | 12 | $12,582 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,337 |
| DexilantDexlansoprazole | 12 | $3,482 |
| Rosuvastatin Calcium | 64 | $1,297 |
| Escitalopram Oxalate | 46 | $907 |
| Bupropion XlBupropion Hcl | 30 | $892 |
| Atorvastatin Calcium | 38 | $730 |
| Gabapentin | 46 | $549 |
| Levothyroxine Sodium | 51 | $544 |
| ProgesteroneProgesterone, Micronized | 13 | $506 |
| ClopidogrelClopidogrel Bisulfate | 29 | $359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $73 | $18,30215 claims |
| PfizerEliquis | $22 | $14,28928 claims |
| Lilly USA, LLCMounjaro | $320 | $12,58212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $17 | $3,48212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,570 hospitalist providers in Florida.
Other hospitalist in Lakewood Ranch
- Murray EpsteinMiami$370K
- Oliver AbelaFort Myers$77K
- Joshua LenchusFort Lauderdale$73K
- Tuncay TaskesenThe Villages$22K
- Diego MunozApopka$17K
- Francisco Perez LoretoMiami$17K
- Tereese AllenTampa$11K
- Timothy LongBay Pines$10K
- Iahn GonsenhauserFort Myers$8K
- Michael ShehataRiverview$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.